# Amphastar Pharmaceuticals, Inc. clinical trials: 21 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 21 trials with Amphastar Pharmaceuticals, Inc. as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Amphastar Pharmaceuticals, Inc.: 21 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/amphastar-pharmaceuticals-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 21
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 21 newest of 21, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| April 30, 2026 | NCT07560150 | Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar/Interchangeable Rapid-Acting Insulin... | Amphastar Pharmaceuticals, Inc. | Phase 2/3 | Completed | Pharmacokinetics, Pharmacodynamics, Insulin Aspart | 62 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07560150) |
| September 14, 2022 | NCT05539872 | Comparison of the Pharmacokinetics (PK) and Pharmacodynamics (PD) Biosimilarity of Proposed Biosimilar Rapid-Acting Insulin Aspart (I004)... | Amphastar Pharmaceuticals, Inc. | Phase 2/3 | Completed | Pharmacokinetics, Pharmacodynamics | 69 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05539872) |
| December 23, 2019 | NCT04207840 | Study of Drug Exposure in Systemic Circulation of Primatene Mist by Oral Inhalation, Versus Epinephrine Injection by Intramuscular... | Amphastar Pharmaceuticals, Inc. | Phase 4 | Completed | Pharmacokinetics, Epinephrine, Albuterol, Asthma, Anaphylaxis | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04207840) |
| October 22, 2014 | NCT02271334 | Evaluation of Pharmacokinetics and Safety of A006 in Healthy Volunteers | Amphastar Pharmaceuticals, Inc. | Phase 2 | Completed | Asthma | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02271334) |
| August 7, 2014 | NCT02210806 | Albuterol DPI (A006) Clinical Study-B3:Efficacy, Dose-ranging and Safety Evaluation | Amphastar Pharmaceuticals, Inc. | Phase 2 | Completed | Asthma | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02210806) |
| November 30, 2012 | NCT01737905 | Evaluation of Efficacy and Safety for Single Dose of E004 in Children With Asthma | Amphastar Pharmaceuticals, Inc. | Phase 3 | Completed | Asthma | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01737905) |
| November 30, 2012 | NCT01737892 | Assessment and Evaluation of Pharmacokinetic Profile of E004 in Healthy Adults | Amphastar Pharmaceuticals, Inc. | Phase 1/2 | Terminated | Asthma | 21 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01737892) |
| September 21, 2012 | NCT01689363 | Evaluation of the Allergenicity of AMPHADASE INJECTION (Hyaluronidase Injection USP) | Amphastar Pharmaceuticals, Inc. | Phase 2 | Completed | Allergic Skin Reaction | 253 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01689363) |
| April 20, 2012 | NCT01581177 | Albuterol DPI (A006) Clinical Study-B2: Efficacy, Dose-Ranging and Initial Safety Evaluation | Amphastar Pharmaceuticals, Inc. | Phase 2 | Completed | Asthma | 23 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01581177) |
| November 22, 2011 | NCT01476904 | Safety Study in Adolescent and Adult Patients With Asthma | Amphastar Pharmaceuticals, Inc. | Phase 3 | Completed | Asthma | 208 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01476904) |
| October 27, 2011 | NCT01460511 | Evaluation of Efficacy and Safety of E004 in Children With Asthma | Amphastar Pharmaceuticals, Inc. | Phase 3 | Completed | Asthma | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01460511) |
| May 23, 2011 | NCT01357642 | Epinephrine Inhalation Aerosol USP: For Evaluation Of Efficacy And Safety In Asthma Patients | Amphastar Pharmaceuticals, Inc. | Phase 3 | Completed | Asthma | 373 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01357642) |
| December 7, 2010 | NCT01255709 | Epinephrine Inhalation Aerosol USP, CLINICAL STUDY-B3 FOR ASSESSMENT OF PHARMACOKINETICS | Amphastar Pharmaceuticals, Inc. | Phase 2 | Completed | Asthma | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01255709) |
| August 26, 2010 | NCT01189396 | Escalating and Cumulative-Dose Study of Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of A006 | Amphastar Pharmaceuticals, Inc. | Phase 2 | Completed | Asthma, Bronchospasm, Chronic Obstructive Pulmonary Disease (COPD) | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01189396) |
| August 25, 2010 | NCT01188577 | Epinephrine Inhalation Aerosol USP, a HFA-MDI Study for Assessment of Pharmacokinetics | Amphastar Pharmaceuticals, Inc. | Phase 1/2 | Completed | Asthma, Bronchospasm, Wheezing, Shortness of Breath | 23 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01188577) |
| August 4, 2010 | NCT01174732 | Dose-Ranging Study of A006 DPI, in Adult Asthma Patients | Amphastar Pharmaceuticals, Inc. | Phase 2 | Completed | Asthma, Bronchospasm | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01174732) |
| June 14, 2010 | NCT01143051 | Pharmacokinetics (PK) Study of Epinephrine Inhalation Aerosol in Healthy Volunteers | Amphastar Pharmaceuticals, Inc. | Phase 1/2 | Completed | Asthma | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01143051) |
| December 3, 2009 | NCT01025648 | Randomized, Placebo/Active Crossover Dose-ranging Study for Safety and Efficacy in Asthma Patients. | Amphastar Pharmaceuticals, Inc. | Phase 1/2 | Terminated | Asthma | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01025648) |
| March 13, 2008 | NCT00635505 | Controlled, 12-Week Study of Albuterol HFA Versus the Active Control, Proventil(R)-HFA in Asthmatic Patients | Amphastar Pharmaceuticals, Inc. | Phase 3 | Terminated | Asthma | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00635505) |
| March 13, 2008 | NCT00634829 | Single-Dose Cross-Over Study of the Effects of Albuterol-HFA in Exercise Induced Bronchoconstriction | Amphastar Pharmaceuticals, Inc. | Phase 3 | Terminated | Asthma, Bronchospasm | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00634829) |
| March 13, 2008 | NCT00634517 | 4-Week Study of Efficacy, Safety and PK of Albuterol-HFA Versus Proventil-HFA in Pediatric Asthma | Amphastar Pharmaceuticals, Inc. | Phase 3 | Terminated | Asthma | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00634517) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1/2 | 4 |
| Phase 2 | 7 |
| Phase 2/3 | 2 |
| Phase 3 | 7 |
| Phase 4 | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 16 |
| Terminated | 5 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Asthma | 18 |
| Dyspnea | 5 |
| Bronchial Spasm | 4 |
| Respiratory Sounds | 3 |
| Pulmonary Disease, Chronic Obstructive | 2 |
| Status Asthmaticus | 1 |
| Anaphylaxis | 1 |
| Hypersensitivity | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Computer training centers in the United States](https://specstream.ai/data/businesses/computer-training-centers/united-states)
- [Basque restaurants in the United States](https://specstream.ai/data/businesses/basque-restaurants/united-states)
- [Adult education centers in the United States](https://specstream.ai/data/businesses/adult-education-centers/united-states)
- [Telecommunications services in the United States](https://specstream.ai/data/businesses/telecommunications-services/united-states)
- [Real estate firms in the United States](https://specstream.ai/data/businesses/real-estate-firms/united-states)
